The use of systemic corticosteroid therapy could reduce mortality for hospitalized adults with community-acquired pneumonia, according to research published in the Annals of Internal Medicine.
The use of systemic corticosteroid therapy could reduce mortality for hospitalized adults with community-acquired pneumonia, according to research published in the Annals of Internal Medicine.
The investigators used data from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials and determined that patients hospitalized with community-acquired pneumonia benefited in multiple ways from the use of corticosteroids.
All-cause mortality fell from about 9% to 5% with the use of this therapy, which also was associated with a reduction in need for mechanical ventilation (by 5%), and acute respiratory distress syndrome. Corticosteroids also decreased time to clinical stability and duration of hospitalization by 1 day for these patients.
“Our study should lead to an important change in treatment for pneumonia,” lead author Reed A.C. Siemieniuk, MD, a physician and a graduate student at McMaster University, said in a statement. “Corticosteroids are inexpensive and readily available around the world. Millions of patients will benefit from this new evidence.”
Lower respiratory infections are the second-most common cause of premature mortality around the world, and community-acquired pneumonia is common in developed countries and can be severe as it is associated with acute respiratory distress syndrome and requires mechanical ventilation.
The international group of researchers (from Canada, Spain, Switzerland, and Norway) analyzed 13 randomized trials that included more than 2000 patients.
“Seldom do we see a major advance in treatment of a condition as common as community-acquired pneumonia,” said Gordon Guyatt, MD, MSc, the study’s senior investigator and a professor of clinical epidemiology and biostatistics at McMaster University. “Corticosteroids over short periods are safe, and we now know that they achieve important benefits in a serious and common medical illness.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More